Jump to main content
Jump to site search


Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing

Author affiliations

Abstract

CRISPR-Cas9, the breakthrough genome-editing technology, has emerged as a promising tool to prevent and cure various diseases. The efficient genome editing technology strongly relies on the specific and effective delivery of CRISPR/Cas9 cargos. However, the lack of a safe, specific, and efficient non-viral delivery system for in vivo genome editing remains a major limit for its clinical translation. In this review, we will first briefly introduce the working mechanism of CRISPR/Cas9 and the patterns of CRISPR/Cas9 delivery. Furthermore, the physiological obstacles for the delivery process in vivo are elaborated. Finally, the key considerations will be deeply discussed in designing non-viral nanovectors for therapeutic CRISPR/Cas9 delivery in vivo, including the effective encapsulation of large-size macromolecules, targeting specific tissues and cells, efficient endosomal escape and safety concerns of the vector systems, in the hope of inviting more comprehensive studies on the development of safe, specific, and efficient non-viral nanovectors for delivering a CRISPR/Cas9 system.

Graphical abstract: Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing

Back to tab navigation

Article information


Submitted
22 Jul 2020
Accepted
01 Oct 2020
First published
05 Oct 2020

Nanoscale, 2020, Advance Article
Article type
Review Article

Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing

Y. Xu, R. Liu and Z. Dai, Nanoscale, 2020, Advance Article , DOI: 10.1039/D0NR05452F

Social activity

Search articles by author

Spotlight

Advertisements